Vaccinate

Great news here at #Hepatology, Medicine and Policy (#HMAP) - We are formally a @PubMedHealth indexed journal (!) & always #openaccess. See our @BioMedCentral home for cutting-edge articles on hepatology, #hepatitis, submission guidelines & more hmap.biomedcentral.com/ @JVLazarus

New review in #HMAP: Strategies for achieving #HCV #microelimination in the Netherlands. Emblematic national ex of connecting highest risk pops to care for @WHO goal: eliminate HCV as #publichealth threat by 2030 #NOhep @BioMedCentral @UniUtrecht @rivm ow.ly/1Elu30m9xE2

New in #HMAP #openaccess: THE #systematicreview of #hepatitis B & C seroprevalence in Nepal 1973-2017. Mobilization for viral hep #elimination requires thorough national data. @UNAIDSNepal @WHOSEARO @gavi @Hep_Alliance @nepalitimes #NOhep #SoutheastAsia hmap.biomedcentral.com/artic…

Just out in #HMAP: Drug consumption rooms as setting to address #hepatitis C – findings from int'l survey #openaccess research on avail of services in #DCRs bit.ly/2wmegt9 @INHepSU @DrugPolicy_DPMP @HRInews @NVHR1 @KirbyInstitute @BioMedCentral #harmreduction #NOhep

New in #Hepatology, Medicine and Policy: Qual research on #patientexperience of achieving #HCV cure using #DAAs in Australia. Finding cure = finding normal - & #PWID must be aware of option for re-treatment @HepAus @LTU_Sex_Health @INHepSU #NOhep #HMAP #openaccess @BioMedCentral

New in #HMAP #openaccess: Researchers quantify #HBV in California, US state w/ highest burden of chronic HBV & related #livercancer in the country. @BioMedCentral @asianliverctr @StanfordMed @Stanford_GI @JVLazarus #NOhep hmap.biomedcentral.com/artic…

New in #HMAP: France removed #hepatitis C #treatment reimbursement restrictions on 25 May 2016. Authors of this report lay out 7 reccs for strengthening impact of this move. Fascinating read/model for across Europe @BioMedCentral @Cermes3 @JVLazarus #NOhep hmap.biomedcentral.com/artic…

Considering central role of people, patient engagement, & communication as #HealthSystem building blocks to effectively support clinical #HCV elimination efforts @JVLazarus. Good morning #EASLmono, let's do some paradigm shifting. @EASLedu @Hep_Alliance @HepatitisEurope #NOhep

Adding enhanced #HCV #testing & #treatment pathways for #PWID and #OST populations, such as pilot trial of community pharmacy pathway projects a >65% reduction in prevalence & prevent significant onward transmission. This is what treatment innovation looks like. #EASLmono #NOhep

Always appreciate Magdalena Harris' work & re-framing dialogue around #HCV and #PWID as heterogeneous populations. Engaged treatment must reach the most marginalized, not just more stable PWID populations. Instead of "tinkering around the edges of elimination" #EASLmono @INHepSU

Philippa Easterbrook echoing @jasongrebely etc but on lessons learned from #HIV, critical need to change from filtering every stage of care through tertiary care clinic, #HCV care should be disseminated in community and delegated to varied providers. #EASLmono

Join those of us at #EASLmono in Berlin. Such a wonderfully full schedule that the discussion is ongoing in person during Q&As and breaks, but on Twitter during the sessions themselves. @EASLedu @aelsharkawy75 @JVLazarus @jasongrebely @AghemoAlessio @StineNielsenEPI and many more

Great talk by Andrea Cox on the possibility and ramifications of potential #HCV #vaccines. We talk about #treatment regularly but she remarks that vaccines have historically been the only way we've fully achieved disease control especially as risk factors vary globally. #EASLmono